PURPOSE: 2-methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17beta metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic activities. Studies with a 2ME2 capsule formulation showed limited oral bioavailability. We report the results of a phase I study using a NanoCrystal Dispersion formulation of 2ME2 (2ME2 NCD). EXPERIMENTAL DESIGN: Patients with refractory solid tumors received 2ME2 NCD orally. Patients received drug either every 6 hours (part A) or every 8 hours (part B). Doses were escalated in successive cohorts until the maximum tolerated dose (MTD) was identified. The primary objective was identifying the MTD. Secondary objectives were to evaluate the plasma pharmacokinetics of 2ME2 and efficacy. RESULTS: In part A, 16 patients received a median of 4 cycles of 2ME2 NCD. Dose-limiting toxicities (DLT) included fatigue (2), hypophosphatemia (2), increased alanine aminotransferase (1), and muscle weakness (1). Trough levels at steady-state reached the minimum effective concentration in all cohorts. The MTD was determined to be 1,000 mg orally every 6 hours. In part B, 10 patients received a median of 1 cycle. DLTs included elevated gamma-glutamyltransferase (1), hyponatremia (1), fatigue (1), and anorexia (1). An MTD could not be defined for part B because 4 of 10 patients had DLTs at the initial dose level and dose reduction was not pursued. Thirteen patients had stable disease (A, 11; B, 2); there were no confirmed responses. CONCLUSION: For 2ME2 NCD, the MTD and recommended phase II regimen is 1,000 mg orally every 6 hours. Treatment was generally well-tolerated.
PURPOSE:2-methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17beta metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic activities. Studies with a 2ME2 capsule formulation showed limited oral bioavailability. We report the results of a phase I study using a NanoCrystal Dispersion formulation of 2ME2 (2ME2 NCD). EXPERIMENTAL DESIGN:Patients with refractory solid tumors received 2ME2 NCD orally. Patients received drug either every 6 hours (part A) or every 8 hours (part B). Doses were escalated in successive cohorts until the maximum tolerated dose (MTD) was identified. The primary objective was identifying the MTD. Secondary objectives were to evaluate the plasma pharmacokinetics of 2ME2 and efficacy. RESULTS: In part A, 16 patients received a median of 4 cycles of 2ME2 NCD. Dose-limiting toxicities (DLT) included fatigue (2), hypophosphatemia (2), increased alanine aminotransferase (1), and muscle weakness (1). Trough levels at steady-state reached the minimum effective concentration in all cohorts. The MTD was determined to be 1,000 mg orally every 6 hours. In part B, 10 patients received a median of 1 cycle. DLTs included elevated gamma-glutamyltransferase (1), hyponatremia (1), fatigue (1), and anorexia (1). An MTD could not be defined for part B because 4 of 10 patients had DLTs at the initial dose level and dose reduction was not pursued. Thirteen patients had stable disease (A, 11; B, 2); there were no confirmed responses. CONCLUSION: For 2ME2 NCD, the MTD and recommended phase II regimen is 1,000 mg orally every 6 hours. Treatment was generally well-tolerated.
Authors: E Merisko-Liversidge; P Sarpotdar; J Bruno; S Hajj; L Wei; N Peltier; J Rake; J M Shaw; S Pugh; L Polin; J Jones; T Corbett; E Cooper; G G Liversidge Journal: Pharm Res Date: 1996-02 Impact factor: 4.200
Authors: G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: Nicola J Mabjeesh; Daniel Escuin; Theresa M LaVallee; Victor S Pribluda; Glenn M Swartz; Michelle S Johnson; Margaret T Willard; Hua Zhong; Jonathan W Simons; Paraskevi Giannakakou Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: Theresa M LaVallee; Xiaoguo H Zhan; Michelle S Johnson; Chris J Herbstritt; Glenn Swartz; Mark S Williams; Wendy A Hembrough; Shawn J Green; Victor S Pribluda Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: S Vincent Rajkumar; Paul G Richardson; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Thomas E Witzig; Robert Schlossman; Carolyn F Sidor; Kenneth C Anderson; Morie A Gertz Journal: Clin Cancer Res Date: 2007-10-15 Impact factor: 12.531
Authors: Tony Fröhlich; Anita Kiss; János Wölfling; Erzsébet Mernyák; Ágnes E Kulmány; Renáta Minorics; István Zupkó; Maria Leidenberger; Oliver Friedrich; Barbara Kappes; Friedrich Hahn; Manfred Marschall; Gyula Schneider; Svetlana B Tsogoeva Journal: ACS Med Chem Lett Date: 2018-10-19 Impact factor: 4.345
Authors: Natalia V Bogatcheva; Marina A Zemskova; Boris A Gorshkov; Kyung Mi Kim; Gregory A Daglis; Christophe Poirier; Alexander D Verin Journal: Am J Respir Cell Mol Biol Date: 2011-06-09 Impact factor: 6.914
Authors: Qing Zhou; Daniel Gustafson; Sujatha Nallapareddy; Sami Diab; Stephen Leong; Karl Lewis; Lia Gore; Wells A Messersmith; Anthony M Treston; S Gail Eckhardt; Carolyn Sidor; D Ross Camidge Journal: Invest New Drugs Date: 2010-01-19 Impact factor: 3.850
Authors: Suman Kambhampati; Roger A Rajewski; Mehmet Tanol; Inamul Haque; Amlan Das; Snigdha Banerjee; Saheli Jha; Douglas Burns; Emma Borrego-Diaz; Peter J Van Veldhuizen; Sushanta K Banerjee Journal: Mol Cancer Ther Date: 2013-01-03 Impact factor: 6.261
Authors: Gordon S Duncan; Dirk Brenner; Michael W Tusche; Anne Brüstle; Christiane B Knobbe; Andrew J Elia; Thomas Mock; Mark R Bray; Peter H Krammer; Tak W Mak Journal: Proc Natl Acad Sci U S A Date: 2012-12-03 Impact factor: 11.205
Authors: Lauren K Dunn; Khalid S Mohammad; Pierrick G J Fournier; C Ryan McKenna; Holly W Davis; Maria Niewolna; Xiang Hong Peng; John M Chirgwin; Theresa A Guise Journal: PLoS One Date: 2009-09-03 Impact factor: 3.240